| Literature DB >> 27897266 |
Fanglin Guan1,2, Huali Lin3, Gang Chen2, Lu Li2, Teng Chen1,2, Xinshe Liu2,4, Jiuqiang Han5, Tao Li2,4.
Abstract
The 5-HT1A receptor (HTR1A) and the 5-HT5A receptor (HTR5A) are key 5-HT receptors with distinct inhibitory functions. Studies have been conducted to investigate the association of a few HTR1A polymorphisms with schizophrenia, producing conflicting results, and the relationship between HTR5A and schizophrenia has not yet been well investigated. We aimed to examine the association of HTR1A and HTR5A with schizophrenia and executive function. The study included a discovery stage with 1,115 patients and 2,289 controls and a replication stage with 2,128 patients and 3,865 controls. A total of 30 common SNPs in HTR1A and HTR5A were genotyped in the discovery stage, and significantly associated SNPs were genotyped in the replication stage. We identified that two SNPs (rs878567 in HTR1A and rs1800883 in HTR5A) were significantly associated with schizophrenia in both datasets, and similar results were observed in imputation and haplotype association analyses. Moreover, we found that SNP rs1800883 significantly interacted with executive function when processing the perseverative error of Wisconsin Card Sorting Test in patients. Our results provide further supportive evidence of the effect of HTR1A and HTR5A on the etiology of schizophrenia and suggest that the selected genetic variations in HTR5A may be involved in impaired executive function.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27897266 PMCID: PMC5126681 DOI: 10.1038/srep38048
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristic information of study subjects.
| Sample stage | Parameters | Case | Control |
|---|---|---|---|
| The Discovery Stage | Male (%) | 535 (47.98) | 1107 (48.36) |
| Female (%) | 580 (52.02) | 1182 (51.64) | |
| Total | 1115 | 2289 | |
| Mean age (SD) | 36.49 (6.78) | 36.42 (9.23) | |
| Age range (years) | 18–47 | 18–47 | |
| The Replication Stage | Male (%) | 1030 (48.40) | 1863 (48.20) |
| Female (%) | 1098 (51.60) | 2002 (51.80) | |
| Total | 2128 | 3865 | |
| Mean age (SD.) | 35.38 (10.39) | 35.53 (11.38) | |
| Age range (years) | 18–57 | 18–57 | |
| Duration of illness (years) (SD) | 5.43 (2.62) | ||
| Total PANSS scores (SD) | 63.21 (11.19) |
SD: standard deviation; PANSS: Positive and Negative Syndrome Scale.
Allele and genotype frequency of single SNP association analysis.
| Dataset | Gene | SNP Affection | H-WE | OR | Allelic count (Freq. %) | Allelic | Genotype count (Freq. %) | Genotypic | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| The discovery dataset | rs878567 | A | GG | GA | AA | ||||||
| SCZ | 0.113 | 1.24 | 1843(82.65) | 387(17.35) | 754(67.62) | 335(30.04) | 26(2.33) | ||||
| CTR | 0.453 | 1.08–1.41 | 3635(79.4) | 943(20.6) | 1449(63.3) | 737(32.2) | 103(4.5) | ||||
| rs6295 | C | G | CC | CG | GG | ||||||
| SCZ | 0.159 | 1.15 | 1711(76.73) | 519(23.27) | 648(58.12) | 415(37.22) | 52(4.66) | ||||
| CTR | 0.634 | 1.02–1.30 | 3392(74.09) | 1186(25.91) | 1261(55.09) | 870(38.01) | 158(6.9) | ||||
| rs1800883 | C | CC | CG | GG | |||||||
| SCZ | 0.339 | 1.21 | 1083(48.57) | 1147(51.43) | 255(22.87) | 573(51.39) | 287(25.74) | ||||
| CTR | 0.847 | 1.09–1.34 | 2439(53.28) | 2139(46.72) | 652(28.48) | 1135(49.58) | 502(21.93) | ||||
| rs6320 | T | A | TT | TA | AA | ||||||
| SCZ | 0.755 | 1.14 | 1453(65.16) | 777(34.84) | 471(42.24) | 511(45.83) | 133(11.93) | 0.055259 | |||
| CTR | 0.807 | 1.02–1.26 | 2847(62.19) | 1731(37.81) | 888(38.79) | 1071(46.79) | 330(14.42) | ||||
| The replication dataset | rs878567 | A | GG | GA | AA | ||||||
| SCZ | 0.479 | 1.19 | 3508(82.42) | 748(17.58) | 1441(67.72) | 626(29.42) | 61(2.87) | ||||
| CTR | 0.969 | 1.08–1.31 | 6169(79.81) | 1561(20.19) | 2462(63.7) | 1245(32.21) | 158(4.09) | ||||
| rs6295 | C | G | CC | CG | GG | ||||||
| SCZ | 0.366 | 1.09 | 3243(76.2) | 1013(23.8) | 0.068321 | 1228(57.71) | 787(36.98) | 113(5.31) | 0.106148 | ||
| CTR | 0.522 | 0.98–1.18 | 5774(74.7) | 1956(25.3) | 2164(55.99) | 1446(37.41) | 255(6.6) | ||||
| rs1800883 | C | CC | CG | GG | |||||||
| SCZ | 0.463 | 1.13 | 2111(49.6) | 2145(50.4) | 532(25) | 1047(49.2) | 549(25.8) | ||||
| CTR | 0.841 | 1.05–1.22 | 4075(52.72) | 3655(47.28) | 1071(27.71) | 1933(50.01) | 861(22.28) | ||||
| rs6320 | T | A | TT | TA | AA | ||||||
| SCZ | 0.684 | 1.08 | 2759(64.83) | 1497(35.17) | 0.058870 | 890(41.82) | 979(46.01) | 259(12.17) | 0.151378 | ||
| CTR | 0.809 | 0.99–1.17 | 4877(63.09) | 2853(36.91) | 1542(39.9) | 1793(46.39) | 530(13.71) | ||||
SCZ: schizophrenia; CTR: control; CI: confidence interval; OR: odds ratio.
1Risk allele and significant P values are in bold italics, and corrected P values are underlined after the Bonferroni correction (P × 30 in the discovery stage and P × 10 in the replication stage). A P-value of 0.05 was chosen as the threshold for significance.
2OR refers to the risk allele odds ratio in cases and controls.
Figure 1LD structure and significantly associated LD blocks based on two-stage data.
LD blocks in HTR1A are indicated by the shaded matrices, and significantly associated LD block 1 in the discovery stage (A) was confirmed in the replication stage (B); LD blocks in HTR5A are indicated by the shaded matrices, and significantly associated LD block 2 in the discovery stage (C) was also confirmed in the replication stage (D). The two associated SNPs (rs878567 and rs1800883) are marked by circles.
Figure 2Regional association plots based on imputed region covering HTR1A and HTR5A.
Imputed SNPs are indicated with a circle, and genotyped SNPs are indicated with a square. The most significant genotyped SNPs were chosen as reference SNPs in the plots (rs878567 and rs1800883).
Common haplotype frequency and association analysis.
| Haplotype | Haplotypic frequency in the discovery stage (%) | Haplotypic frequency in the replication stage (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| SCZ | CTR | Global | SCZ | CTR | Global | |||
| 79.2 | 76.8 | 80.2 | 78.2 | |||||
| AGGC | 8.56 | 10.5 | 8.93 | 9.96 | 0.069 | |||
| AGAT | 7.26 | 7.62 | 0.512 | 7.83 | 8.24 | 0.344 | ||
| 46.5 | 51.6 | 48.5 | 52.1 | |||||
| CACG | 35.0 | 36.4 | 0.265 | 36.7 | 38.0 | 0.176 | ||
| 10.4 | 6.81 | 8.88 | 6.76 | |||||
| 4.88 | 2.71 | 3.94 | 1.50 | |||||
SCZ: schizophrenia; CTR: control. Significant haplotypes and P values are in bold italics. Rare haplotypes are not shown if the frequency is less than 1%. A P-value of 0.05 was chosen as the threshold for significance.
1Based on 10000 permutations.
2Based on comparison of frequency distribution of all haplotypes for the combination of SNPs.
Comparisons of executive function of 2 associated SNPs in patients and controls.
| Subjects | SNP/Genotype | PE | NPE | TE | TCFC |
|---|---|---|---|---|---|
| Schizophrenia patients | rs878567 ( | ||||
| GG | 31.52 (0.17) | 38.73 (0.10) | 70.24 (0.20) | 67.57 (0.11) | |
| GA | 31.95 (0.26) | 38.50 (0.15) | 70.44 (0.30) | 67.55 (0.16) | |
| AA | 32.85 (0.83) | 39.33 (0.48) | 72.18 (0.98) | 67.60 (0.51) | |
| 0.139 | 0.179 | 0.144 | 0.992 | ||
| rs1800883 ( | |||||
| CC | 31.29 (0.28) | 38.66 (0.16) | 69.95 (0.33) | 67.47 (0.18) | |
| CG | 31.52 (0.20) | 38.63 (0.12) | 70.15 (0.24) | 67.78 (0.12) | |
| GG | 32.37 (0.27) | 38.79 (0.15) | 70.14 (0.32) | 67.24 (0.17) | |
| 0.725 | |||||
| non-GG | 31.44 (0.16) | 38.64 (0.10) | 70.08 (0.19) | 67.68 (0.10) | |
| GG | 32.37 (0.27) | 38.79 (0.15) | 70.14 (0.32) | 67.24 (0.17) | |
| 0.435 | |||||
| Healthy controls | rs878567 ( | ||||
| GG | 5.630 (0.052) | 13.689 (0.062) | 19.319 (0.082) | 22.171 (0.105) | |
| GA | 5.470 (0.074) | 13.713 (0.087) | 19.184 (0.115) | 21.898 (0.147) | |
| AA | 5.822 (0.201) | 13.625 (0.236) | 19.447 (0.314) | 22.268 (0.401) | |
| 0.104 | 0.932 | 0.548 | 0.285 | ||
| rs1800883 ( | |||||
| CC | 5.551 (0.08) | 13.727 (0.09) | 19.278 (0.12) | 22.140 (0.16) | |
| CG | 5.584 (0.06) | 13.694 (0.07) | 19.278 (0.093) | 22.071 (0.12) | |
| GG | 5.636 (0.09) | 13.653 (0.10) | 19.289 (0.14) | 22.057 (0.18) | |
| 0.77 | 0.867 | 0.998 | 0.923 | ||
PE: perseverative errors; NPE: non-perseverative errors; TE: total errors; TCFC: trials to compete first category. Data are shown as the mean, and all standard errors (SE) are indicated in the parentheses. P values were adjusted for age, gender, duration of illness and PANSS (Positive and Negative Syndrome Scale) in patients and for only age and gender in controls. A P-value of 0.05 was chosen as the threshold for significance, and significant P values are in bold italics.